Curative Introduces Zero First, Flipping the Traditional Health Insurance Deductible on Its Head

Curative launched Zero First, a health plan for eligible level-funded employer groups starting December 1, 2026, that keeps designated routine care at $0 while the plan covers other eligible in-network care up to a set amount. Standard EPO terms include a $2,500 initial coverage amount, 30% subsequent cost sharing and an $8,000 individual out-of-pocket maximum; the PPO option uses $5,000, 25% and $6,350, respectively. Curative’s modeling based on 2025 membership data estimates 69% of EPO and 78% of PPO members would have paid $0 for in-network medical care, versus an estimated 24% under a typical $3,000-deductible plan; these are modeled outcomes, not guarantees.

Analysis

The investment signal is product competition, not an immediate earnings event: availability is limited to eligible level-funded employer groups, and the article provides no enrollment, premium, or claims data. The key test is whether employers choose Zero First at renewal without Curative absorbing worse risk. A richer first-dollar design may improve take-up and reduce care deferral, but could also raise routine utilization; the net claims effect depends on whether earlier access substitutes for more costly later care. In level-funded arrangements, adverse selection and claims volatility matter as much as the headline benefit design.

Curative’s own modeled $0-care rates are not independently verified and are based on its membership; its lower 2026 tracking figures versus 2025 estimates caution against extrapolating the launch claims. Baseline Visit requirements also create an execution and member-compliance dependency. Incumbent carriers and benefits administrators could respond with similar low-friction plan options, limiting differentiation and pricing power. Conversely, if this design wins employer groups, it may pressure traditional deductible-led offerings and increase broker demand for more differentiated plan choices.

Near term, the announcement alone is unlikely to move public insurers materially. Over 1–3 months, watch broker uptake, eligible-group quotes and Dec. 1 effective-date enrollment. Over 6–18 months, claims per member, renewal retention and employer pricing will determine whether the design scales profitably. Curative’s launch does not establish a sector-wide shift; there is no clean public-market exposure to the product itself.

Key Decisions for Investors

• No trade on the announcement alone. Treat it as a watch item rather than evidence of a material change to listed managed-care earnings.
• Monitor public carriers and benefits administrators for comparable plan launches or employer-retention commentary; a broader shift toward lower upfront member costs could intensify competition, but could also increase utilization.
• For any future Curative exposure, require evidence on enrollment, renewal retention, claims per member and risk-adjusted pricing before underwriting growth. Falsification: persistently higher claims without offsetting retention or pricing gains, or weak uptake at Dec. 1 effective dates.